Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 4 to 5 amino acid residues in defined sequence
Reexamination Certificate
2007-08-14
2007-08-14
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
4 to 5 amino acid residues in defined sequence
C514S017400, C514S018700, C424S178100, C424S181100
Reexamination Certificate
active
10476391
ABSTRACT:
Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
REFERENCES:
patent: 3445518 (1969-05-01), Chambers
patent: 4414205 (1983-11-01), Pettit
patent: 4694778 (1987-09-01), Learn et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816444 (1989-03-01), Pettit et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4879278 (1989-11-01), Pettit et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4978744 (1990-12-01), Pettit et al.
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5225539 (1993-07-01), Winter
patent: 5410024 (1995-04-01), Pettit et al.
patent: 5521284 (1996-05-01), Pettit et al.
patent: 5530097 (1996-06-01), Pettit et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5554725 (1996-09-01), Pettit
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5599902 (1997-02-01), Pettit et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5635483 (1997-06-01), Pettit et al.
patent: 5654399 (1997-08-01), Sakakibara et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5663149 (1997-09-01), Pettit et al.
patent: 5665860 (1997-09-01), Pettit et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5741892 (1998-04-01), Barlozzari et al.
patent: 5767236 (1998-06-01), Kim et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5780588 (1998-07-01), Pettit et al.
patent: 5840699 (1998-11-01), Sakakibara et al.
patent: 5965537 (1999-10-01), Ritter et al.
patent: 6004934 (1999-12-01), Sakakibara et al.
patent: 6034065 (2000-03-01), Pettit et al.
patent: 6124431 (2000-09-01), Sakakibara et al.
patent: 6143721 (2000-11-01), Janssen et al.
patent: 6162930 (2000-12-01), Pinney et al.
patent: 6239104 (2001-05-01), Pettit et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 7098308 (2006-08-01), Senter et al.
patent: 2001/0018422 (2001-08-01), Ritter et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2005/0180972 (2005-08-01), Wahl et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2005/0272665 (2005-12-01), Schmid et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0128970 (2006-06-01), Bliss et al.
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: 0 695 757 (1996-02-01), None
patent: 0 695 758 (1996-02-01), None
patent: 0 695 758 (1996-02-01), None
patent: 0 695 759 (1996-02-01), None
patent: 0 695 759 (1996-02-01), None
patent: 06234790 (1994-08-01), None
patent: 09077791 (1997-03-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 86/05807 (1986-10-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 89/01036 (1989-02-01), None
patent: WO 93/03054 (1993-02-01), None
patent: WO 93/08829 (1993-05-01), None
patent: WO 94/04690 (1994-03-01), None
patent: WO 95/09864 (1995-04-01), None
patent: WO 96/14856 (1996-05-01), None
patent: WO 96/14856 (1996-05-01), None
patent: WO 96/33212 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 99/35164 (1999-07-01), None
patent: WO 01/018032 (2001-03-01), None
patent: WO 03/008378 (2003-01-01), None
patent: WO 2004/010957 (2004-02-01), None
Beidler et al., 1988, “Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen,” J. Immunol. 141(11):4053-4060.
Better et al., 1988, “Escherichia colisecretion of an active chimeric antibody fragment,” Science 240(4855):1041-1043.
Bird, 1988, “Single-chain antigen-binding proteins,” Science 242(4877):423-426.
Bowen et al., 1993, “Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation,” J. Immunol. 151(11):5896-5906.
Bowman et al. 1950, “N-substituted Amino-acids. Part I. A New Method of Preparation of Dimethylamino-acids”, J. Chem. Soc. 1342-1340.
Breitling et al., 1998, “New Functions Through Heterologous Fusion Partners: Bifunctional Antibodies”, Recombinanat Antibodies, Ch. 3, 91-93.
Clackson et al., 1991, “Making antibody fragments using phage display libraries,” Nature 352(6336):624-628.
Cockett et al., 1990 “High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification,” Biotechnology (NY) 8(7):662-667.
Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96.
Francisco et al., 2000, “Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14,” Cancer Res. 60(12):3225-3231.
Frankel et al., 2000, “Cell surface receptor-targeted therapy of acute myeloid leukemia: a review,” Cancer Biother. Radiopharm. 15(5):459-476.
Frisch et al., 1996, “Synthesis of short polyoxyethylene-based Heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes,” Bioconjug. Chem. 7(2):180-186.
Goldspiel et al., 1993, “Human gene therapy,” Clin. Pharm. 12(7):488-505.
Hanes et al., 1997, “In vitro selection and evolution of functional proteins by using ribosome display,” Proc. Natl. Acad. Sci. USA 94(10):4937-4942.
Jespers et al., 1994, “Guiding the selection of human antibodies from phage display repertoirs to a single epitope of an antigen,” Biotechnology (NY) 12(9):899-903.
Jones et al., 1986, “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature 321(6069):522-525.
King et al., 1999, “Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates,” Bioconjug. Chem. 10(2):279-288.
Kütemeier et al., 1994, “Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR,” Biotechniques 17(2):242-246.
Liu et al., 1987, “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity,” J. Immunol. 139(10):3521-3526.
Liu et al., 1987, “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,” Proc. Natl. Acad. Sci. USA 84(10):3439-3443.
Miyazaki et al., 1995, “Synthesis and antitumor activity of novel dolastatin 10 analogs,” Chem. Pharm. Bull. (Tokyo) 43(10):1076-1718.
Murray et al., 2000, “Monoclonal antibody treatment of solid tumors: a coming of age,” Semin. Oncol 27(6 Suppl 11):64-70.
Pettit, 1998, “Antineoplastic agents 365. Dolastatin 10 SAR probes,” Anticancer Drug Des. 13(4):243-277.
Pettit, 1997, “The dolastatins,” Fortschr. Chem. Org. Naturst. 70:1-79.
Pettit et al., 1996, J. Chem. Soc. Perk I pp. 859.
Pettit et al., 1995, “Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications,” Anticancer Drug Des. 10(7):529-544.
Shaw et al., 1988, “Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses,” J. Natl. Cancer Inst. 80(19):1553-1559.
Pollack et al., 1988, “Introduction of nucleophiles and spectroscopic probes into antibody combining sites,” Science 1988 242(4881):1038-1040.
Trail et al., 1997, “Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates,” Cancer Res. 57(1):100-105.
Trail et al., 1993, “Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates,
Doronina Svetlana
Senter Peter D.
Toki Brian E.
Lukton David
Seattle Genetics Inc.
Woodcock & Washburn LLP
LandOfFree
Pentapeptide compounds and uses related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pentapeptide compounds and uses related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pentapeptide compounds and uses related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855199